MedPath

Etoricoxib

Generic Name
Etoricoxib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H15ClN2O2S
CAS Number
202409-33-4
Unique Ingredient Identifier
WRX4NFY03R
Background

Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.

Indication

For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.

Associated Conditions
Ankylosing Spondylitis (AS), Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Moderate Pain
Associated Therapies
-

Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients

Phase 2
Completed
Conditions
HIV
Interventions
First Posted Date
2011-01-04
Last Posted Date
2017-05-31
Lead Sponsor
Dag Kvale
Target Recruit Count
60
Registration Number
NCT01269515
Locations
🇳🇴

Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway

🇳🇴

The Biotechnology Centre, University of Oslo, Oslo, Norway

Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain

Phase 4
Conditions
Postherpetic Neuralgia
Neuralgia
Interventions
Drug: Placebo
Drug: Etoricoxib
First Posted Date
2010-12-21
Last Posted Date
2011-03-23
Lead Sponsor
Analgesic Solutions
Target Recruit Count
120
Registration Number
NCT01264237
Locations
🇬🇧

MAC (UK) Neuroscience Ltd, Manchester, United Kingdom

🇬🇧

MAC (UK) Neruoscience Ltd, Liverpool, United Kingdom

Efficacy Study of Pre-emptive Etoricoxib for Postoperative Pain and Functional Outcome in Total Knee Arthroplasty

Phase 2
Completed
Conditions
Knee Osteoarthritis
Interventions
Drug: Control
Drug: Etoricoxib
First Posted Date
2010-11-23
Last Posted Date
2017-02-10
Lead Sponsor
Singapore General Hospital
Target Recruit Count
65
Registration Number
NCT01246362
Locations
🇸🇬

Singapore General Hospital, Singapore, Singapore

Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty

Phase 3
Completed
Conditions
Perioperative Blood Loss
Arthroplasties Hip Replacement
Coxarthrosis
Interventions
First Posted Date
2010-10-28
Last Posted Date
2014-09-15
Lead Sponsor
University of Regensburg
Target Recruit Count
100
Registration Number
NCT01229774
Locations
🇩🇪

Department of Orthopedic Surgery, Bad Abbach, Bavaria, Germany

A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain

Phase 4
Withdrawn
Conditions
Postoperative Pain
Hallux Valgus
Interventions
First Posted Date
2010-08-30
Last Posted Date
2017-12-02
Lead Sponsor
Karolinska Institutet
Registration Number
NCT01190722

Trial of Etoricoxib (Arcoxia) Taken Prophylactically to Prevent Ramadan Headache

Phase 4
Completed
Conditions
Headache
Fasting
Fasting Headache
Ramadan Headache
Interventions
Drug: Etoricoxib
Drug: Placebo
First Posted Date
2010-06-22
Last Posted Date
2011-03-08
Lead Sponsor
Hartford Hospital
Target Recruit Count
220
Registration Number
NCT01148303
Locations
🇮🇱

Shaare Zedek Medical Center, Jerusalem, Israel

Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs

Phase 3
Completed
Conditions
Ankylosing Spondylitis
Interventions
First Posted Date
2010-03-24
Last Posted Date
2015-08-25
Lead Sponsor
Spanish Foundation of Rheumatology
Target Recruit Count
58
Registration Number
NCT01091675
Locations
🇪🇸

Hospital General of Mostoles, Madrid, Spain

🇪🇸

Central Hospital of Asturias, Oviedo, Asturias, Spain

🇪🇸

Sant Rafael Hospital, Barcelona, Spain

and more 11 locations

Efficacy of Etoricoxib on Peripheral Hyperalgesia

Phase 2
Terminated
Conditions
Causalgia
Polyneuropathy
Postherpetic Neuralgia
Peripheral Nerve Injury
Radiculopathy
Interventions
Drug: Etoricoxib
Drug: placebo
First Posted Date
2010-03-17
Last Posted Date
2012-08-24
Lead Sponsor
Ruhr University of Bochum
Target Recruit Count
9
Registration Number
NCT01088256
Locations
🇩🇪

Bergmannsheil department of pain therapy, Bochum, Nordrhein-Westfalen, Germany

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Completed
Conditions
Ankylosing Spondylitis
Interventions
Other: No anti-inflammatory treatment
Drug: Etoricoxib
Drug: Other Cox-2 inhibitors
Drug: Other Non-selective NSAIDs
First Posted Date
2010-03-01
Last Posted Date
2022-02-18
Lead Sponsor
Organon and Co
Target Recruit Count
27381
Registration Number
NCT01077843

Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)

Phase 4
Withdrawn
Conditions
Rheumatoid Arthritis
Interventions
First Posted Date
2010-02-11
Last Posted Date
2021-06-23
Lead Sponsor
Northumbria Healthcare NHS Foundation Trust
Registration Number
NCT01067430
Locations
🇬🇧

Northumbria Healthcare NHS Foundation Trust, North Shields, Tyne And Wear, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath